Okay, lets see how the panel will discuss these points:
Point 1-3: patients from 001 trial used the same lot of cells. thus, there is little variability of TNFR1 expression in the same lot of cells. the outcome (ie: responder vs non-responder) might be purely attributed to variability in patients and their immune system and disease severity/stage.
Point 4: Significant was observed (as shown by SI) the optimized protocol produced better outcome. But importantly, TNFR1 expression level correlates with survival/better outcome.
Ryoncil: ODAC/FDA Meeting Discussion, page-402
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.020(1.81%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.12 | $4.898M | 4.355M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 596693 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 50805 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.13 |
Change
0.020 ( 0.92 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.12 | 1420559 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| MSB (ASX) Chart |